Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Bortezomib
Drug ID BADD_D00284
Description Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma.[A204083] The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib.[L14180] However, multiple mechanisms may be involved in the anticancer activity of bortezomib.[A204083] Bortezomib was first synthesized in 1995.[A204083] In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE.[A204146] Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.[A214307]
Indications and Usage For treatment of multiple myeloma in patients who have not been successfully treated with at least two previous therapies.
Marketing Status Prescription
ATC Code L01XG01
DrugBank ID DB00188
KEGG ID D03150
MeSH ID D000069286
PubChem ID 387447
NDC Product Code 67184-0026; 62207-972; 54893-0011; 65129-1264; 63759-0006; 63020-049; 70225-1102; 42973-140; 78848-009; 68554-0051; 54245-7004; 14096-140; 27629-267; 12502-5268; 48957-0018; 55111-922; 62756-982; 63323-721; 62158-0011; 76055-0027; 47848-031; 66529-0006
Synonyms Bortezomib | LDP-341 | LDP 341 | LDP341 | PS 341 | 341, PS | PS-341 | PS341 | Velcade
Chemical Information
Molecular Formula C19H25BN4O4
CAS Registry Number 179324-69-7
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abdominal pain lower07.01.05.010--Not Available
Abdominal pain upper07.01.05.003--
Abdominal rigidity07.01.05.0110.000533%Not Available
Abdominal wall abscess11.01.07.018; Available
Abnormal faeces07.01.03.001--Not Available
Acne23.02.01.001--Not Available
Acute febrile neutrophilic dermatosis23.03.03.033; Available
Acute lymphocytic leukaemia16.01.01.001; Available
Acute myeloid leukaemia16.01.05.001; Available
Acute myocardial infarction24.04.04.001; Available
Acute pulmonary oedema22.01.03.005; Available
Acute respiratory distress syndrome22.01.03.0010.000208%
Acute respiratory failure22.02.06.001; Available
Affective disorder19.04.04.001--Not Available
Ageusia17.02.07.001; Available
Agranulocytosis01.02.03.0010.001332%Not Available
Alanine aminotransferase increased13.03.01.003--
Alcohol intolerance14.02.01.001--
Amyloidosis10.02.05.0010.000695%Not Available
Anal fissure07.03.01.002--
Anaphylactic reaction24.06.03.006;
Anaphylactic shock24.06.02.004; Available
The 1th Page    1 2 3 4 5    Next   Last    Total 28 Pages